Drug Trial Radar · NCT05562947
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Jun 17, 2024
Primary completion
Jun 30, 2027
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese participants with nAMD.
Conditions
- Neovascular Age-related Macular Degeneration
- nAMD
Interventions
PDS With Ranibizumab (100 mg/mL)Device
Participants randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 microliters (μL) of the 100 mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for participants randomized to the IVT arm. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed 24-week intervals.
Ranibizumab (10 mg/mL)Drug
Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterwards, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44 and bi-monthly visits thereafter, followed by visits every two months until study completion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-corrected Visual Acuity (BCVA) Score Averaged Over Weeks 36 and 40, as Assessed Using the ETDRS Visual Acuity (VA) Chart at a Starting Distance of 4 MetersTime frame: Baseline up to Week 40
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
Beijing Tongren Hospital
Beijing, China
West China Hospital, Sichuan University
Chengdu, China
Sichuan Provincial People's Hospital
Chengdu, China
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, China
Qingdao Eye Hospital of Shandong First Medical University
Qingdao, China
Shanghai First People's Hospital
Shanghai, China
The First Affiliated Hospital of China Medical University
Shenyang, China
Shanxi Eye Hospital
Taiyuan, China
Tianjin Medical University Eye Hospital
Tianjin, China
Eye Hospital, Wenzhou Medical University
Wenzhou, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Xi'an People's Hospital (Xi'an Fourth Hospital)
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.